PDF herunterladen
CC BY-NC-ND 4.0 · South Asian J Cancer 2016; 05(02): 037-047
DOI: 10.4103/2278-330X.181623
Editorial

Selected current data on metronomic therapy (and its promise) from India

P. M. Parikh
Department of Precision Oncology, Asian Cancer Institute, Sion East, Mumbai, Maharashtra
,
S. S. Hingmire
Department of Oncology, Deenanath Mangeshkar Hospital, Erandwane, Pune, Maharashtra
,
C. D. Deshmukh
Department of Oncology, Deenanath Mangeshkar Hospital, Erandwane, Pune, Maharashtra
› Institutsangaben Financial support and sponsorship: Nil.
› Weitere Informationen
Auch verfügbar auf
  als PDF herunterladen Lizenzen und Reprints


Publikationsverlauf

Artikel online veröffentlicht:
28. Dezember 2020

© 2016. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Patil V, Noronha V, Krishna V, Joshi A, Prabhash K. Oral metronomic chemotherapy in recurrent, metastatic and locally advanced head and neck cancers. Clin Oncol (R Coll Radiol) 2013;25:388.
  • 2 Patil V, Karpe A, Noronha V, Joshi A, Muddu V, Bhattacharjee A, et al. Efficacy of second-line erlotinib in patients postprogression of first-line chemotherapy in head and neck cancers. Indian J Cancer 2015;52:629-31.
  • 3 Noronha V, Joshi A, Marfatia S, Patil V, Juvekar S, Arya S, et al. Health-related quality of life in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of the head and neck in India. Support Care Cancer 2016;24:1595-602.
  • 4 Patil VM, Noronha V, Joshi A, Muddu VK, Dhumal S, Bhosale B, et al. A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. Oral Oncol 2015;51:279-86.
  • 5 Pai PS, Vaidya AD, Prabhash K, Banavali SD. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous cell cancers: A matched-pair analysis. Indian J Cancer 2013;50:135-41.
  • 6 Majumder D, Mukherjee A. Mathematical modelling of toxicity-related trade-offs in metronomic chemotherapy. IET Syst Biol 2007;1:298-305.
  • 7 Noronha V, Tsomo U, Jamshed A, Hai M, Wattegama S, Baral R, et al. A fresh look at oncology facts on south central Asia and SAARC countries. South Asian J Cancer 2012;1:1-4.
  • 8 André N, Pasquier E. Metronomics in low and middle income countries: India showing the way! Indian J Cancer 2013;50:112-4.
  • 9 Bouche G, André N, Banavali S, Berthold F, Berruti A, Bocci G, et al. Lessons from the fourth metronomic and anti-angiogenic therapy meeting, 24-25 June 2014, Milan. Ecancermedicalscience 2014;8:463.
  • 10 Tandon N, Banavali S, Menon H, Gujral S, Kadam PA, Bakshi A. Is there a role for metronomic induction (and maintenance) therapy in elderly patients with acute myeloid leukemia? A literature review. Indian J Cancer 2013;50:154-8.
  • 11 Malik PS, Raina V, André N. Metronomics as maintenance treatment in oncology: Time for chemo-switch. Front Oncol 2014;4:76.
  • 12 Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O′Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.
  • 13 Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36.
  • 14 Noronha V, Krishna MV, Patil V, Joshi A, Banavali SD, Prabhash K. Metronomic therapy: Chemotherapy revisited. Indian J Cancer 2013;50:142-8.
  • 15 Bahl A, Bakhshi S. Metronomic chemotherapy in progressive pediatric malignancies: Old drugs in new package. Indian J Pediatr 2012;79:1617-22.
  • 16 Agrawal A, Purandare N, Shah S, Puranik A, Banavali S, Rangarajan V. Response assessment in metronomic chemotherapy: RECIST or PERCIST? Indian J Nucl Med 2014;29:74-80.
  • 17 Sondhi V, Arun Kurkure P, Jalali R, Rangarajan V, Sridhar E, Medhi S, et al. Complete remission and long-term survival in a child with relapsed medulloblastoma with extensive osteosclerotic bony metastasis with a novel metronomic chemobiological approach. J Pediatr Hematol Oncol 2012;34:e195-8.
  • 18 Parikh PM, Prabhash K, Bhattacharyya GS, Sirohi B, Rajappa S, Verma A, et al. Ignore molecular oncology at your peril. Indian J Cancer 2014;51:150-3.